<?xml version="1.0" encoding="UTF-8"?>
<p id="p0015">The Third Hospital of Jilin University (THJU) is managed by China National Health Commission (CNHC) which is a large-scale Grade III-A hospital, with an annual outpatient service of about 1.84 million patients. The hospital was specified as the first provincial-level COVID-19 diagnosis and treatment unit in Jilin Province.
 <xref rid="bib3" ref-type="bibr">
  <sup>3</sup>
 </xref> During COVID-19 outbreak-period, the pressure of medical service has increased. Efficient pharmaceutical practices could provide support for responding to the COVID-19 pandemic.
 <xref rid="bib4" ref-type="bibr">
  <sup>4</sup>
 </xref> The Pharmaceutical Department of THJU has carried out a series of work in terms of drug supply and pharmaceutical service, which has provided effective support for prevention, control and treatments of COVID-19. As of March 31,2020, the mortality rate of patients with COVID-19 in THJU was 0%, the number of infected medical staff was nil.
</p>
